Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision | ||
project_bioshield [2022/07/20 21:27] pamela | project_bioshield [2022/07/20 22:21] (current) pamela | ||
---|---|---|---|
Line 1: | Line 1: | ||
===== Project Bioshield ===== | ===== Project Bioshield ===== | ||
+ | |||
+ | ==== Background ==== | ||
+ | |||
+ | April 25, 2002 | ||
+ | |||
+ | Jim Rarey is a freelance writer based in Romulus, Michigan. He is a former newspaper editor and investigative reporter, a retired customs administrator and accountant, and a student of history and the U.S. Constitution. | ||
+ | |||
+ | |||
+ | Now comes a new " | ||
+ | |||
+ | Aside from the involvement of for-profit companies in the effort, another major difference from Homeland Defense is that the man in charge is not a part of the government. | ||
+ | |||
+ | The nominal head of the industry’s effort comes through its trade association [[: | ||
+ | |||
+ | Friedman will interface with a number of government agencies, including HHS, The Dept. of Defense, the FDA, NIH, and the CDC, and oh yes, Homeland Security. Holmer did not say whether Friedman would be making use of the association’s lone consultant (as listed on its webpage) Arthur Andersen, LLP. | ||
+ | |||
+ | Friedman himself is a 30-year veteran of government service in public health. He was a leader in the FDA, and at one time, its acting commissioner. Friedman was the FDA official who gave the Department of Defense the go ahead to use the [[:anthrax vaccine]] in the Gulf war even though the FDA had not found it to be safe or effective against inhalation anthrax. | ||
+ | |||
+ | But Friedman is no longer in government. He is currently a senior vice president of the pharmaceutical giant [[: | ||
+ | |||
+ | In April 2000, three well-known companies combined to form the Pharmacia Corporation: | ||
+ | |||
+ | The current Chairman of the Board and CEO of Pharmacia is a Pakistani named [[:Fred Hassan]]. Hassan was President of Pharmacia-Upjohn at the time of the merger with Monsanto, and moved into his current position after Monsanto’s CEO had served an interim 18-month period as head of the combined companies. | ||
+ | |||
+ | There are a couple of well-known names on the Pharmacia Board of Directors, and one whose name has only recently come into the public consciousness. | ||
+ | |||
+ | [[:William Ruckelshaus]] is a Harvard-trained lawyer who came out of the Justice Department to become the first administrator of the new [[: | ||
+ | |||
+ | [[:Michael (Mickey) Kantor]] is a close confidante of Bill Clinton and served in his administration first as the United States Trade Representative (USTR). Kantor took over as Commerce Secretary following the controversial death of Ron Brown. Kantor was one of the point men involved in blunting some of the Clinton personal scandals, including the Kathleen Willey affair. | ||
+ | |||
+ | Dr. [[:Philip Leder]], although a virtual unknown outside of medical circles, has impressive credentials. He is Chairman of the [[: | ||
+ | |||
+ | Perhaps the most controversial member of Pharmacia’s board is [[:Frank Carlucci]]. Carlucci is Chairman of the Board and CEO of the [[:Carlyle Group]], which describes itself as a " | ||
+ | |||
+ | The Carlyle board of directors reads like a class reunion of former cabinet members from past Republican administrations. However, Carlucci himself seemed equally at home under Democrat and Republican presidents during his checkered career in public service. | ||
+ | |||
+ | In the 1950s and 1960s, Carlucci was a foreign service officer ostensibly in the State Department, although some alleged that was cover for his [[:CIA]] activities. Indeed, he served as Deputy Director of the CIA in the Carter administration. He served in foreign posts in the Congo and Brazil when Communist or pro-Communist governments were overthrown, as well as ambassador to Portugal when that government fell. | ||
+ | |||
+ | Carlucci held several sub-cabinet level positions in the Nixon Administration. As Deputy Secretary of Defense under [[:Caspar Weinberger]] in the Reagan administration, | ||
+ | |||
+ | Although Pharmacia will likely be first among equals in influencing PhRMA’s involvement in bioterrorism, | ||
+ | |||
+ | Numbered among the 66 members is [[:Bayer]], the German firm that returned to profitability through the surge in sales of its antibiotic [[:Cipro]] following the mailed anthrax incidents last year. | ||
+ | |||
+ | Surprisingly, | ||
+ | |||
+ | However, under the radar of the [[: | ||
+ | |||
+ | A common thread in the fabric of this web is the presence of two giant foundations; | ||
+ | |||
+ | In a three part series (Anthrax, GOCO’s and Designer Germs) this writer detailed [[: | ||
+ | |||
+ | Researchers [[:Leonard Horowitz]] and [[:Patricia Doyle]] have catalogued the extensive involvement and control by [[:HHMI]] of research on the human genome. **At least six microbiologists in that field with ties to HHMI have been murdered or died mysterious deaths (five since 9/11/01**). | ||
+ | |||
+ | **One of the undercurrents in the development of the ability to change genes is the documented effort by scientists in several countries (including the U.S.) to turn the science into production of deadly designer diseases that attack only specific segments of the population.** | ||
+ | |||
+ | According to an undercover FBI informant, American scientist [[:Larry Ford]] (who had ties to the CIA) designed an agent for the South African bioweapon program that would affect only blacks. Ford later was considered a suspect in the attempted murder of his business partner, and died from a shotgun blast that was ruled a suicide. | ||
+ | |||
+ | One of the concerns of researchers, | ||
+ | |||
+ | A second concern is with the vaccines and other " | ||
+ | |||
+ | These (unconstitutional) " | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | ==== Bioshield II ==== | ||
Biological Weapons Experts Call for Revisions to BioShield II Legislation | Biological Weapons Experts Call for Revisions to BioShield II Legislation |